Abstract: CB-2 is associated with shorter procedure time, left atrial dwell time, and length of stay after ablation, as well as lower ERAA, but its costs and fluoroscopy time are greater than the RF group. Moreover, the rate of complications and long-term success is similar between the two groups.
Introduction
Atrial fibrillation (AF) represents a significant health burden in China, affecting approximately 10 million individuals, with prevalence increasing sharply among the elderly. Catheter ablation (CA) is a standard treatment for drug-resistant AF; however, patients over 75 years old are often underrepresented in clinical trials due to concerns regarding frailty and comorbidities. This study compares two primary ablation technologies—second-generation cryoballoon (CB-2) and radiofrequency (RF)—to determine their relative safety, efficacy, and cost-effectiveness in this high-risk population within the Chinese healthcare context.
Methods
This retrospective cohort study analyzed 324 consecutive elderly patients (>75 years) who underwent their first pulmonary vein isolation (PVI) at a center in Hangzhou between 2016 and 2019. The cohort was divided into a CB-2 group (n=148) and an RF group (n=176). RF ablation utilized a 3D electroanatomic mapping system (Carto 3) for point-by-point lesions, while CB-2 used a 28-mm cryoballoon for circumferential freezing. Follow-up lasted 24 months, monitoring for arrhythmia recurrence via ECG and 24-hour Holter monitoring. A comprehensive cost analysis was performed, including equipment, diagnostic, medication, and general medical expenses.
Results and Discussion
Procedural Efficiency and Radiation Exposure
The CB-2 approach demonstrated superior procedural efficiency, with significantly shorter procedure times (112.9 vs. 135.1 min) and left atrial dwell times compared to RF. However, this efficiency comes at the cost of increased radiation exposure; CB-2 relies more heavily on fluoroscopy for balloon positioning, whereas RF utilizes sophisticated 3D mapping to reduce X-ray dependence.
Early Outcomes and Economic Impact
CB-2 was associated with a lower rate of Early Recurrence of Atrial Arrhythmia (ERAA) (14.2% vs. 23.3%, P = 0.047). This may be due to the nature of "cold" injury, which potentially creates more uniform lesions with less post-procedural inflammation compared to the heat-induced edema seen in RF.
Despite shorter hospital stays for CB-2 patients (1.94 vs. 2.53 days), the total procedural cost was significantly higher for the CB-2 group (~91,132 vs. ~81,149 CNY). This economic paradox is driven by the high cost of specialized cryoballoon catheters and disposable supplies in the Chinese market.
Long-term Success and Safety
Over the 24-month follow-up period, the initial advantages of CB-2 in preventing early recurrence did not translate into superior long-term outcomes. Kaplan-Meier survival curves for both groups converged, showing no statistically significant difference in freedom from atrial tachyarrhythmia at two years (79.1% for CB-2 vs. 75.6% for RF). Safety profiles were also comparable, with low complication rates in both cohorts.
Conclusion
For elderly patients in China, CB-2 ablation offers faster procedures and shorter hospital stays with reduced early recurrence. However, these benefits are offset by higher equipment costs and increased radiation exposure. Given the similar long-term success and safety profiles, the choice between CB-2 and RF may depend on institutional resources and operator preference. Future improvements in RF technology, such as "Ablation Index" guidance, may further narrow the efficiency gap between these two modalities.
Summary updated